Cancer cells recruit monocytes, macrophages and other inflammatory cells by producing abundant chemoattractants and growth factors, such as macrophage colony-stimulating factor (M-CSF/CSF-1) and monocyte chemoattractant protein-1 (MCP-1/CCL2), to promote tumor growth and dissemination. An understanding of the mechanisms that target cancer cells and regulate tumor microenvironment is essential in designing anticancer therapies. Here, we showed that serum amyloid-A (SAA) and cathelicidin (LL-37) stimulated M-CSF and MCP-1 expression with or without lipopolysaccharide (LPS) administration; conversely, lipoxin-A 4 (LXA 4 ) and annexin-A1 (ANXA1) inhibited LPS-induced M-CSF and MCP-1 production by human (HepG2) and mouse (H22) hepatocellular carcinoma cells (HCCs). The effects of LXA 4 , ANXA1, SAA and LL-37 were dependent on the activation of their mutual cell-surface receptor formyl peptide receptor-2 (FPR2) and subsequent ROS-MAPK-NF-kB signalings. Furthermore, our results indicated that LPS switched macrophages into an IL-10 low IL-12 high M1 profile, whereas M-CSF þ MCP-1 and FPR2 agonists skewed them into M2 (IL-10 high IL-12 low ). In that respect, through modulating the phosphorylation of signal transducer and activator of transcription-3 (STAT3), LXA 4 and ANXA1 induced monocyte differentiation into M2a þ M2c-like cells and showed antitumorigenetic activities, whereas SAA, LL-37 and M-CSF þ MCP-1 led to M2b-or M2d-like polarization, which exacerbated HCC invasion in vitro and in vivo, respectively. Our results suggest that FPR2 has an appreciable pleiotropic regulator role in tumor immunoediting.
Introduction
Over a century ago, Virchow hypothesized a link between inflammation and cancer on the basis of the presence of leukocytes in neoplastic tissues. Since then, masses of epidemiological studies and experimental findings have supported the concept that, under many conditions, tumor development and progression are largely orchestrated by inflammation (Balkwill and Mantovani, 2001 ). More recent evidence indicates that the disruption of endogenous mechanisms that drive the resolution of inflammation could result in chronic inflammation and tumor promotion (Lawrence, 2007; Spite and Serhan, 2010) .
Macrophages are pivotal factors in tumor immunoediting. The paradoxical ambivalent relationship between macrophages and cancer reflects the functional plasticity of these cells (Allavena et al., 2008) . Macrophages can differentiate into two subsets, classically activated macrophages (or M1) and alternatively activated macrophages (or M2), on the basis of their ability to produce interleukin-12 (IL-12) or IL-10, respectively. M1 has potent microbicidal properties and promotes Th1 responses, whereas M2 supports Th2-associated effector functions (Mills et al., 2000; Martinez et al., 2008) . M2 macrophages are further subdivided into M2a, M2b, M2c and M2d cells as elicited by different stimuli (Sironi et al., 2006; Martinez et al., 2008; Duluc et al., 2009 ). M2a and M2b macrophages exert immune regulatory functions and drive Th2 responses, whereas M2c macrophages have a predominant role in suppressing immune responses and in promoting tissue remodeling. M2d macrophages, also termed tumorassociated macrophages (TAMs), which accumulate at the tumor site by tumor-derived signals, such as macrophage colony-stimulating factor (M-CSF/CSF-1) and monocyte chemoattractant protein-1 (MCP-1, or chemokine (C-C motif) ligand-2 CCL2), contribute actively to tumor tolerance and impair the efficacy of antitumor immunotherapies (Varney et al., 2002; Pollard, 2004) .
Formyl peptide receptor-2 (FPR2, also termed formyl peptide receptor-like-1 or lipoxin-A 4 receptor ALX), a member of the chemoattractant receptor subfamily of G-protein-coupled receptors (GPCRs), has complex functional properties, partially because of its high promiscuity, and also because of the fact that activation of the receptor can either stimulate or inhibit the inflammation response, depending on the ligands of different origins and high structural diversity (Ye et al., 2009) . In addition to the important roles in inflammation, FPR2 is also implicated in cancer (De et al., 2000; Cocco et al., 2010) . Elucidating the exact mechanism of FPR2 involved in tumorigenesis is crucial for better understanding inflammation and cancer pathophysiology, and designing a potent anticancer therapeutic strategy.
In this study we observed the effects of four structurally diverse FPR2 agonists, lipoxin-A 4 (LXA 4 ), serum amyloid-A (SAA), annexin-A1 (ANXA1) and cathelicidin (LL-37), on the expression levels of M-CSF and MCP-1 in human (HepG2) and mouse (H22) hepatocellular carcinoma cells (HCCs). Moreover, we found that these agonists skewed the macrophages into distinct M2 subtypes and showed opposing roles on HCC tumorigenesis in vitro and in vivo. These results provided a novel insight into the possible regulatory mechanism of FPR2 in tumor immunoediting.
Results

Effects of FPR2 agonists on M-CSF and MCP-1 production in HCCs
As shown in Figure 1 , both mRNA and protein expression levels of M-CSF and MCP-1 in HepG2 and H22 cells were significantly upregulated by SAA and LL-37.
However, after exposure to the other two agonists LXA 4 and ANXA1, the levels of M-CSF and MCP-1 did not alter remarkably. In addition, compared with control groups, endotoxin lipopolysaccharides (LPSs) increased the mRNA and protein levels of M-CSF and MCP-1 remarkably, whereas LXA 4 and ANXA1 reversed the effect of LPS on the expressions of M-CSF and MCP-1. Intriguingly, SAA and LL-37 enhanced the accumulation of M-CSF and MCP-1 induced by LPS (Supplementary Figure S1 ). These results indicated that diverse FPR2 agonists could have opposing roles in M-CSF and MCP-1 accumulation in HCCs.
The regulatory action of FPR2 agonists on the expression levels of M-CSF and MCP-1 is partially due to the expression and activity of NF-kB The transcription factor nuclear factor-kB (NF-kB) is well known to have an important role in the process of inflammation and its resolution (Panzer et al., 2009) . In agreement with the results cited above, the expression of NF-kB p50 increased in HepG2 cells treated with SAA, LL-37 or LPS. SAA also enhanced the accumulation of NF-kB p50 induced by LPS. Conversely, LXA 4 and ANXA1 reduced the expression of NF-kB p50. LXA 4 reversed the increase of NF-kB p50 induced by LPS (Figure 2a, top) . Consistently, the binding activities of NF-kB were significantly enhanced after treatment with SAA, LL-37 or LPS, whereas no apparent change was observed after stimulation with LXA 4 or ANXA1. Figure 1 Effects of FPR2 agonists on the expressions of M-CSF and MCP-1. After HepG2 and H22 cells were treated with LXA 4 (100 nM), SAA (100 nM), ANXA1 (100 nM) or LL-37 (50 mg/ml) for 24 h, the mRNA expression (a) and protein secretion (b) of M-CSF and MCP-1 were detected by real-time PCR and ELISA, respectively. *Po0.05 versus control (untreated). In this and subsequent experiments, the error bars indicate s.e.m.; data are representative of at least three experiments. ANXA1, annexin-A1; FPR2, formyl peptide receptor-2; LXA 4 , lipoxin-A 4 ; MCP-1, monocyte chemoattractant protein-1; M-CSF, macrophage colony-stimulating factor; SAA, serum amyloid-A.
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Y Li et al SAA boosted whereas LXA 4 completely suppressed the transcriptional activity of NF-kB stimulated by LPS (Figure 2a, bottom) . Furthermore, knockdown of NF-kB p50 with RNA interference inhibited the binding activity of NF-kB and partially attenuated the production of M-CSF and MCP-1 induced by SAA, whereas it had no effect on M-CSF and MCP-1 expressions with LXA 4 treatment (Figures 2b and c) , suggesting that NF-kB is involved in the regulation of FPR2 in the production of M-CSF and MCP-1.
ROS and MAPKs are involved in the regulation of FPR2 in M-CSF and MCP-1 accumulation As many agents activating NF-kB are modulated by reactive oxygen species (ROS) and/or by mitogenactivated protein kinases (MAPKs) (Janssen-Heininger et al., 1999), we questioned whether the effects of FPR2 agonists could also occur via the ROS and/or MAPK pathways. As shown in Figure 3a , ROS level increased after exposure to LPS, SAA and LL-37. LXA 4 and ANXA1 alone did not alter ROS level, but LXA 4 impaired ROS generation induced by LPS. The level of phosphorylated ERK (pERK) dramatically increased after exposure to SAA and LL-37. SAA also induced the activation of phosphorylated p38 (pp38), whereas LL-37 had no effect on pp38. Conversely, both LXA 4 and ANXA1 suppressed the phosphorylation of ERK and p38 (Figure 3b ).
To determine whether ROS preceded or followed MAPK activation in the FPR2-NF-kB-M-CSF/MCP-1 signaling axis, diphenyleneiodonium (DPI, a ROS generation inhibitor), PD98059 (a specific inhibitor of pERK) and SB203580 (a pp38 inhibitor) were used. As shown in Figures 3c and d , inhibitors of both ROS and MAPKs reduced the expressions of NF-kB p50, M-CSF and MCP-1 induced by SAA. It was noteworthy that DPI attenuated ROS generation and expression levels of pERK and pp38 induced by SAA, whereas the MAPK inhibitors PD98059 and SB203580 failed to reduce ROS production, suggesting that ROS is upstream of MAPKs. Of interest, neither PD98059 and SB203580 nor DPI showed obvious change in the levels of ROS and MAPKs upon LXA 4 administration (Figures 3c and d) . These experiments indicated that Figure 2 Regulation FPR2 on M-CSF and MCP-1 is partially due to NF-kB activity. (a) HepG2 cells were incubated with LXA 4 (100 nM), SAA (100 nM), ANXA1 (100 nM), LL-37 (50 mg/ml) and LPS (1 mg/ml) for 24 h; the expressions (top) and binding activity (bottom) of NF-kB p50 were detected. (b) After HepG2 cells were transfected with scrambled and p50 short interfering RNAs for 48 h, the expression and binding activity of NF-kB p50 were examined by western blotting (top) and luciferase assay (bottom), respectively. (c) After transfection with scrambled and p50 short interfering RNAs for 72 h, HepG2 cells were incubated with LXA 4 (100 nM) or SAA (100 nM) for 24 h, and the mRNA expression and protein secretion of M-CSF (left) and MCP-1 (right) were detected by real-time PCR and ELISA, respectively. *Po0.05, **Po0.01 versus control (untreated); # Po0.05 versus LPS group; w Po0.05 versus scrambled group. ANXA1, annexin-A1; FPR2, formyl peptide receptor-2; LPS, lipopolysaccharide; LXA 4 , lipoxin-A 4 ; MCP-1, monocyte chemoattractant protein-1; M-CSF, macrophage colony-stimulating factor; NF-kB, nuclear factor-kB; SAA, serum amyloid-A. SAA and LXA 4 also exert their functions through Toll-like receptor (TLRs) and leukotriene-B 4 receptor (BLT1) activation, respectively (Chiang et al., 2006; Sandri et al., 2008) . In our study, E5564 (TLR inhibitor) and U-75302 (BLT1 antagonist) suppressed the binding of 
Effects of FPR2 agonists on macrophage polarization
Undoubtedly, adjusting TAM phenotypes should be a potent therapeutic strategy for suppressing tumor progression. The macrophage-related cell line U937 has been examined as surrogate for TAMs in many in vitro studies (Craig et al., 2008) . Here, we detected U937 macrophage z Po0.05 versus SAA group. ANXA1, annexin-A1; DPI, diphenyleneiodonium; FPR2, formyl peptide receptor-2; LPS, lipopolysaccharide; LXA 4 , lipoxin-A 4 ; MAPK, mitogen-activated protein kinase; MCP-1, monocyte chemoattractant protein-1; M-CSF, macrophage colony-stimulating factor; NF-kB, nuclear factor-kB; ROS, reactive oxygen species; SAA, serum amyloid-A.
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Y Li et al polarization upon administration of the above agonists in vitro. As shown in Figure 5a , compared with the control group, LPS inhibited IL-10 but stimulated IL-12p35 production, which is the phenotype of M1 cells, whereas M-CSF þ MCP-1 and FPR2 agonists skewed U937 cells into IL-10 high IL-12p35 low (M2).
Pertussis toxin (PTX) blocked these changes, suggesting that all these agents stimulated macrophage differentiation through GPCR activation. Furthermore, we showed that the FPR2 antagonist WRW4 impaired the effects of LXA 4 /ANXA1 and SAA/LL-37 on the induction of IL-10 or IL-12p35 (Figure 5a ). These We next questioned which subsets were induced by the FPR2 agonists and M-CSF þ MCP-1. The IL-12p40 subunit is shared by IL-23, another heterodimeric cytokine that has biological activities distinct from IL-12 (Oppmann et al., 2000) . IL-23 is an important part of the inflammatory response against infection and development of cancer (Peng et al., 2010; Teng et al., 2010) . In our study, IL-23p19 expression was enhanced by LPS, M-CSF þ MCP-1, SAA and LL-37, but not by LXA 4 or ANXA1 (Figure 5b) .
The inflammatory cytokines that have the most convincing tumor-promoting activity in a range of animal models are IL-6, IL-1b and tumor necrosis factor-a (TNFa); each of these cytokines can be considered as a therapeutic target (Kuninaka et al., 2000) . In our study, their expression levels were also upregulated by LPS and by M-CSF þ MCP-1 and SAA. LL-37 increased the level of IL-6 and IL-1b, whereas it did not show significant effect on TNFa protein accumulation compared with the control group (untreated). No difference was observed in the expression levels of IL-23p19, IL-6 and IL-1b among the control (untreated), LXA 4 and ANXA1 groups. But TNFa was inhibited by LXA 4 and ANXA1 (Figure 5b ). These results proved that SAA and LL-37 aggravated the tumor. Our findings also suggested a novel signaling pathway showing that LXA 4 and ANXA1 inhibited tumorigenesis through attenuating the expression of IL-6, IL-1b and TNFa by macrophages in the tumor microenvironment.
Production of CCL17, CCL1, chemokine (C-X-C motif) ligand-13 (CXCL13) and CXCL8 (IL-8) has been proven to be associated with an M2a, M2b, M2c and M2d monocyte activation program, respectively, and are parts of mononuclear phagocyte-mediated regulatory circuits of innate and adaptive immunity (Mills et al., 2000; Sironi et al., 2006; Martinez et al., 2008; Duluc et al., 2009; Wang et al., 2010; Zhang et al., 2010a) . As shown in Figure 5c , CCL17 levels markedly increased whereas CCL1 did not show apparent change upon M-CSF þ MCP-1, LXA 4 and ANXA1 administration. Secretions of both CXCL13 and CXCL8 were promoted by M-CSF þ MCP-1. Among the FPR2 agonists, LXA 4 and ANXA1 promoted CXCL13 but did not increase CXCL8 accumulation. On the contrary, SAA and LL-37 enhanced CXCL8 secretion, whereas they did not affect CXCL13 production significantly.
To further confirm these results, we then compared the mRNA expression levels of these phenotypes in tumor-infiltrating macrophages (TIMs) from in situ tumor tissue using real-time PCR (Supplementary Figure S2) . The macrophages of the control group were isolated from the peritonea of untreated mice. Consistent with the in vitro study, the macrophages in the H22 group showed an M2d-like profile (high levels of IL-10, IL-23p19, IL-6, IL-1b, TNFa, CCL17, CCL1 and CXCL8; low expressions of IL-12p35 and CXCL13). Although ANXA1 and LL-37 skewed the macrophages into M2 (IL-10 high IL-12p35 low ), they had distinct roles in the induction of macrophage subsets. IL-23p19, IL-6, IL-1b, TNFa, CCL1 and CXCL8 were inhibited by ANXA1, whereas they were conspicuously induced by Figure 5 FPR2 mediates U937 cell polarization. U937 cells were incubated with LPS (1 mg/ml), recombinant human M-CSF (10 ng/ml) þ MCP-1 (10 ng/ml), LXA 4 (100 nM), ANXA1 (100 nM), SAA (100 nM), LL-37 (50 mg/ml), PTX (100 ng/ml) and WRW4 (10 mM) for 72 h; the expressions of IL-10, IL-12p35 (a), IL-23p19, IL-6, IL-1b, TNFa (b), CCL17, CCL1, CXCL13 and CXCL8 (c) were analyzed by ELISA. zz Po0.01 versus the LL-37 group. ANXA1, annexin-A1; CCL, chemokine (C-C motif) ligand; CXCL, chemokine (C-X-C motif) ligand; FPR2, formyl peptide receptor-2; IL, interleukin; LPS, lipopolysaccharide; LXA 4 , lipoxin-A 4 ; MCP-1, monocyte chemoattractant protein-1; M-CSF, macrophage colony-stimulating factor; PTX, pertussis toxin; SAA, serum amyloid-A; TNF, tumor necrosis factor.
Y Li et al LL-37. Production of CCL17 and CXCL13 was significantly evoked by ANXA1 but showed negligible change by LL-37 (Supplementary Figure S2C) . Together, these results suggested that LXA 4 /ANXA1, SAA/LL-37 and M-CSF þ MCP-1 skewed the macrophages into M2a þ M2c-like, M2b-like and M2d-like subsets, respectively.
STAT3 phosphorylation is responsible for FPR2-mediated M2 subset differentiation
Signal transducers and activators of transcription-3 (STAT3) have an instructive role in inflammation and tumorigenesis (Aggarwal et al., 2009) . Activated STAT3 induces the expression of suppressor of cytokine signaling-3 (SOCS3), which subsequently inhibits STAT3 signaling feedback (Miao et al., 2006) . To test whether FPR2 agonists and M-CSF þ MCP-1 affected STAT3 activity in macrophages, U937 cells were incubated with LXA 4 , SAA, M-CSF þ MCP-1 and/or NSC74859 (a STAT3-specific inhibitor). The protein expression levels of SOCS3 and phosphorylated STAT3 (pSTAT3) were examined ( Figure 6a ). SOCS3 expression was induced by FPR2 agonists; however, neither M-CSF þ MCP-1 nor NSC74859 triggered Because STAT3 was found to regulate immune activation and macrophage function (Kortylewski et al., 2009) , it is tempting to speculate that activated STAT3 could have a role in macrophage polarization. The secretion of CCL17, CCL1, CXCL13 and CXCL8 was analyzed as shown in Figure 6b . On one hand, the STAT3 inhibitor NSC74859 alleviated the accumulation of CCL17 and CXCL13 proteins elicited by LXA 4 . M-CSF þ MCP-1 markedly enhanced CCL17 and CXCL13 secretion induced by LXA 4 , whereas there were no significant changes in CCL17 and CXCL13 between the LXA 4 group and SAA þ LXA 4 group. On the other hand, LXA 4 did not affect CCL1 expression induced by SAA, whereas it blunted the CXCL8 secretion evoked by M-CSF þ MCP-1. Together, these results suggested that pSTAT3 was responsible for LXA 4 -induced M2a þ M2c-like differentiation and M-CSF þ MCP-1-triggered M2d-like polarization; however, it was not M-CSF þ involved in the FPR2 agonist SAA-mediated CCL1 secretion.
FPR2 is involved in HCC tumorigenesis
As shown in Figure 7a , significant upregulations of HepG2 cell proliferation (about 4.23-and 5.1-fold) were observed in the SAA and LL-37 groups, whereas LXA 4 and ANXA1 inhibited the proliferation to 0.63-and 0.57-fold, respectively. To address the effect of macrophages on HCC proliferation in vitro, we co-cultured HepG2 cells in U937-conditioned medium (after various treatments). Compared with the control group, co-cultivation in neither untreated U937-nor ANXA1-treated U937-conditioned medium led to any remarkable change in HepG2 cell proliferation, whereas co-cultivation in M-CSF þ MCP-1-treated and LL-37-treated U937-conditioned medium significantly enhanced the proliferation of HepG2 cells (Figure 7b ).
In the tumor microenvironment, HIF-1 (hypoxiainducible factor-1) and COX-2 (cyclooxygenase-2) have important roles in cancer cell survival, proliferation, angiogenesis and metastasis (Colotta et al., 2009; Greenhough et al., 2009; Li and Ye, 2010) . In our study, HIF-1a could not be detected in control (untreated) and ANXA1-stimulated HepG2 cells; however, it was induced in LL-37-stimulated HepG2 cells (Figure 7c ). After co-cultivation with M-CSF þ MCP-1-treated or LL-37-treated U937-conditioned medium, HIF-1a was also induced. ANXA1-treated U937 cells only led to slight HIF-1a expression. Likewise, ANXA1 or co-cultivation with untreated or ANXA1-treated U937-conditioned medium did not change COX-2 levels significantly, whereas LL-37 and co-cultivation with LL-37-treated U937-conditioned medium greatly increased COX-2 expression in HepG2 cells (Figure 7c ). These observations were further confirmed using the subcutaneous xenograft mice model. As shown in Figures 7d and e, compared with the control group (H22-bearing mice), the weight and volume of dissected tumor tissue decreased in the ANXA1 group but increased in the LL-37 group. In addition, HIF-1a and COX-2 expressions of the tumor tissue were inhibited by ANXA1, whereas they were enhanced by LL-37 (Figure 7f) . However, the densities of TIMs increased in the ANXA1 and LL-37 groups (Supplementary Figure  S3) . Although WRW4 alone altered neither the weight and volume nor the expression levels of HIF-1a and COX-2 in the tumor, it mildly impaired the infiltration of macrophages in situ and obviously suppressed the effects of ANXA1 and LL-37 on tumorigenesis and macrophage infiltration in the tumor microenvironment (Figures 7d-f and Supplementary Figure S3) , suggesting that ANXA1 and LL-37 regulated tumor growth by activating FPR2 in vivo.
Discussion
FPR2 is the first typical PTX-sensitive, seven-transmembrane GPCR to be shown to interact with ligands spanning lipids, proteins and peptides (Gao and Murphy, 1993; Ye et al., 2009 ). On one hand, FPR2 has been comprehensively assessed for its anti-inflammatory pharmacology, which includes abilities to provoke deactivation and detachment of leukocytes, leukocyte apoptosis, and increment of phagocytosis of apoptotic cells by phagocytes and regulation of COX-2. The most striking attribute of FPR2 anti-inflammatory pharmacology is related to its putative endogenous ligands, such as LXA 4 and ANXA1 (Fiore et al., 1992; El Kebir et al., 2008) .
LXs are endogenous eicosanoids generated from arachidonic acid through the transcellular biosynthetic pathway by lipoxygenases. The results from other groups and from ours have outlined a role for LXs as anti-inflammatory and pro-resolution mediators (Serhan et al., 1984; McMahon et al., 2000; Zhang et al., 2007; Serhan et al., 2008) . Glucocorticoid-induced inhibition of phospholipase-A2 was mediated by a second messenger named lipocortin-1 or annexin-A1 (Pepinsky et al., 1986) . Several studies have linked inhibition of inflammatory mediators by glucocorticoid with ANXA1-dependent pathways in both monocytes and macrophages (Perretti et al., 2002b) . Acetylation of COX-2 by glucocorticoid and aspirin can trigger 15-epi-LXA 4 biosynthesis (Perretti et al., 2002a) . Intriguingly, glucocorticoid and non-steroidal antiinflammatory drugs have provided potential treatments for cancer (Coimbra et al., 2009; Zhang et al., 2010b) . Hence, ANXA1 and LXs may be involved in the anti-inflammation and anticancer role as COXs inhibitors.
On the other hand, by binding other ligands such as SAA and cathelicidin LL-37, FPR2 also assumes a proinflammatory role such as chemoattraction and activation of human neutrophils, monocytes and T cells, and amplification of innate and adaptive immune responses, thereby modulating chemoattraction, dendritic cell differentiation, mast cell degranulation and angiogenesis stimulation (Su et al., 1999; De et al., 2000) . Hence, it is a highly controversial receptor that regulates inflammation and immunity.
In many solid tumors, overexpression of M-CSF and MCP correlates with poor prognosis. Here, we showed that the FPR2 agonists SAA and LL-37 promoted the generation of ROS, the phosphorylation of MAPKs, the expression and transactivation of NF-kB, and eventually the production of M-CSF and MCP-1 in HCCs. LXA4 and ANXA1, however, promoted M-CSF and MCP-1 accumulation in the mRNA and protein levels through the ROS-MAPKs-NF-kB pathway. Using a ligand binding assay, PTX, RNA interference against FPR2 and the antagonist WRW4, we showed that the four agonists fulfilled the opposing role by binding to different sites of their mutual plasma membrane receptor FPR2.
The propensity for tumors to progress and metastasize reflects not only the oncogenic mutations in the cancer cells but also dynamic interactions involving nonmalignant cells in the tumor microenvironment. Compelling evidence has emerged in recent years showing macrophages being recruited to sites of solid tumor formation in vivo in response to chemoattractant signals, such as M-CSF and MCP-1, secreted by cancer cells and fulfilling an important role in tumor invasion into surrounding normal tissues, proliferation and survival, and metastasis to local and distant sites (Varney et al., 2002; Duluc et al., 2007; Fujimoto et al., 2009) . Our results provided the first evidence that M-CSF þ MCP-1 and the structurally distinct FPR2 ligands induced monocyte differentiation into different M2 subtypes. Thereinto, LXA 4 and ANXA1 induced M2a þ M2c-like polarizations and showed an antitumor activity, whereas, intriguingly, SAA and LL-37 skewed the macrophages into M2b-like and M-CSF þ MCP-1 switched macrophages into M2d-like subsets. Both M2b-and M2d-like cells promoted HCC invasion in vitro and in vivo. In addition, this study revealed a novel phenomenon that not all M2 cells promote tumorigenesis, and proposed that IL-23, IL-6, IL-1b and TNFa could be considered as important biomarkers for M1 and TAMs.
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In summary, FPR2 activation by structurally distinct agonists (LXA 4 , ANXA1, SAA and LL-37) triggered the PTX-sensitive G-protein-mediated signaling cascade, which pleiotropically regulated M-CSF/MCP-1 signaling and the tumor microenvironment, thus fulfilling the role of a double-edged sword in macrophage polarization, and aided in releasing inflammatory mediators and in tumorigenesis (Figure 8) . Because of the complex network between inflammation and cancer, FPR2 is therefore prone to constitute an attractive family of pharmacological targets for cancer therapy. However, before that, important questions such as a more molecular basis for FPR2-mediated macrophage polarization and whether the proresolution effects of LXs have a critical role in the balance between tumor immunity and inflammation await an answer. Furthermore, a better understanding of the specific TAMs phenotypes and the different functions of M2a and M2c macrophages in tumorigenesis could provide opportunities for selectively blocking tumor-promoting activity and, possibly, enhancing the intrinsic antitumor potential of macrophages. During the past few years, substantial progress has been made in the cognition of the biological roles of the once elusive FPR2. Although the function of FPR2 expressed in cancer cells is a subject of further investigation, this receptor may have a broader functional role beyond that of mediating tumor immunoediting.
Materials and methods
Cell culture
Mouse H22 cells, human U937 cells and HepG2 cells were obtained from American Type Culture Collection (Manassas, VA, USA) and cultured at 37 1C in a humidified atmosphere with 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, USA).
In the co-culture experiments, U937 cells were inoculated at a density of 3 Â 10 6 cells per well in six-well plates. After treatment with drugs for 72 h, the medium was collected and filtered through a 0.22-mm filter and used as U937-conditioned medium. HepG2 cells were inoculated at a density of 3 Â 10 6 cells per well in six-well plates in the U937-conditioned medium for 36 h; as controls, tumor cells were grown in Dulbecco's modified Eagle's medium (supplemented with 10% fetal bovine serum).
Cell proliferation analysis
HepG2 cells were inoculated at a density of 1 Â 10 6 cells per well in 96-well plates in the U937-conditioned medium; as controls, tumor cells were grown in Dulbecco's modified Eagle's medium (supplemented with 10% fetal bovine serum). After culture for 36 h, 10 ml of CCK-8 solution was added to each well of the plate. Then the plate was incubated at 37 1C for 4 h. Absorbance was recorded at 450 nm using a microplate reader.
Mice model
Experiments were conducted with virus-free female BALB/c mice aged 6 to 8 weeks. The mice experiment protocols were approved by the Institutional Animal Care and Use Committee at Harvard Medical School. For implantation of tumor, cells were harvested by exposure to 0.05% trypsin-EDTA and then resuspended in Hank's balanced salt solution (HBSS) at a concentration of 2 Â 10 6 cells/ml. Mice were injected subcutaneously with 150 ml of the cell suspension, administering 3 Â 10 5 cells per mouse. An injection site was chosen on the dorsum of the animals, between the scapulae. In the treatment groups, ANXA1 and LL-37 were injected through the tail vein on days 1, 8 and 15, respectively (0.1 ml, final dosage 1 mg/kg).
Isolation of TIMs in the tumor stroma Three weeks after tumor implantation the mice were killed by CO 2 asphyxiation. Tumors were carefully dissected, and freed of skin and surrounding tissues. After measuring weight and volume, the tumors were cut into fragments. The TIMs were isolated as described by Duff et al. (2007) . Briefly, the tissue fragments were washed in HBSS before being transferred to a conical tube containing 0.05% collagenase (hepatocyte-qualified collagenase; Life Technologies Inc., Carlsbad, CA, USA) at 37 1C. The tissue was kept in collagenase for 20 min with gentle agitation using a magnetic stirring rod. Then the sample was passed through a 70-mm mesh to yield a single-cell suspension. These cells were then spun at 1500 r.p.m., the collagenase-containing supernatant was aspirated and the pellet was resuspended in calcium-and magnesium-free HBSS. The cells were washed twice before being finally resuspended in complete HBSS at a concentration of 10 million cells/ml. Cell viability was assessed using a Trypan Blue exclusion test and was 498%. (For detecting the density of TIMs, these cells were stained with anti-CD68-PE (BD Biosciences, San Jose, CA, USA) and analyzed by fluorescence-activated cell sorting; the results are shown in Supplementary Figure S3. ) For isolating macrophages, these cells were plated on 10-cm tissue culture dishes at 5 ml per dish and allowed to adhere for 40 min at 37 1C. After this time period, the plates were washed with HBSS to remove all non-adherent cells. Such a short time for adherence was chosen to prevent contamination of the cell population by tumor cells, which had begun to adhere after 1 h. With this method, the cell population of macrophages achieved was 495%. 
